Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records

Þorsteinsson H, Baukmann HA, Sveinsdóttir HS, Halldórsdóttir DÞ, Grzymala B, Hillman C, Rolfe-Tarrant J, Parker MO, Cope JL, Ravarani CNJ, Schmidt MF, Karlsson KÆ.

Neuropsychopharmacology. 2025 Jun;50(7):1145-1155. doi: 10.1038/s41386-025-02062-x.

https://www.nature.com/articles/s41386-025-02062-x

Article

Feb 14, 2025